VYNE Therapeutics Inc. (VYNE) |
|
6.29 -0.24 (-3.68%)
|
05-31 11:47 |
|
Open: |
6.6 |
Pre. Close: |
6.53 |
|
High:
|
6.6 |
Low:
|
6.26 |
|
Volume:
|
11,751 |
Market Cap:
|
21(M) |
|
|
|
Technical analysis |
as of: 2023-05-31 11:50:36 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 8.09  One year: 10.19 |
| Support: |
Support1: 4.03 Support2: 3.35 |
| Resistance: |
Resistance1: 6.93 Resistance2: 8.72 |
| Pivot: |
6.87 |
| Moving Average: |
MA(5): 6.68 MA(20): 6.97 
MA(100): 4.3 MA(250): 5.1 |
| MACD: |
MACD(12,26): 0.4 Signal(9): 0.6 |
| Stochastic oscillator: |
%K(14,3): 28.6 %D(3): 35.4 |
| RSI: |
RSI(14): 50.7 |
| 52-week: |
High: 9.89 Low: 1.99 |
| Average Vol(K): |
3-Month: 760 (K) 10-Days: 32 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ VYNE ] has closed above bottom band by 20.7%. Bollinger Bands are 11.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.71 - 6.75 |
6.75 - 6.78 |
|
Low:
|
6.21 - 6.26 |
6.26 - 6.3 |
|
Close:
|
6.46 - 6.54 |
6.54 - 6.59 |
|
Company Description |
|
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey. |
Headline News |
Mon, 29 May 2023
Rosacea Market to Witness Upsurge in Growth During the Forecast ... - Digital Journal
Fri, 26 May 2023
Topical Use Acne Treatment Industry 2030 Expected to reach ... - Scene for Dummies: Everything Hollywood Undead
Thu, 18 May 2023
Is Vyne Therapeutics Inc (VYNE) a Smart Choice in Biotechnology Thursday? - InvestorsObserver
Fri, 12 May 2023
Why Heron Therapeutics Shares Are Trading Lower By 34%? Here Are Other Stocks Moving In Friday’s Mid-Day - Benzinga
Thu, 11 May 2023
VYNE Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Yahoo Finance
Fri, 05 May 2023
Inhaled IPF therapy VYN201 eases fibrosis in mouse model |... - Pulmonary Fibrosis News
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
3 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
1.5 (%) |
|
% Held by Institutions
|
13.4 (%) |
|
Shares Short
|
207 (K) |
|
Shares Short P.Month
|
98 (K) |
Stock Financials |
|
EPS
|
-9.19 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
9.65 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
0 |
|
Return on Assets (ttm)
|
0 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.14 |
|
Sales Per Share
|
0 |
|
EBITDA (p.s.)
|
0 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.69 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
0.65 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
